U NOVARTIS

Novartis Kisqali[®] shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease

May 27, 2020

Source URL: https://prod1.novartis.com/us-en/news/media-releases/novartis-kisqali-shows-overall-survival-benefit-hrher2-advanced-breast-cancer-consistent-findings-patients-more-aggressive-disease-0

List of links present in page

1. https://prod1.novartis.com/us-en/us-en/news/media-releases/novartis-kisqali-shows-overall-survivalbenefit-hrher2-advanced-breast-cancer-consistent-findings-patients-more-aggressive-disease-0